Cardiovascular Rounds

New study says we're closing the gender gap on TAVR short-term outcomes

by Marissa Schwartz

The widespread growth of TAVR has created pressure to continually improve both short-term and long-term outcomes. Historically, studies have shown women to have a higher post-TAVR survival rate than men, but an increased risk of early bleeding. However, recent research presented at the Society for Cardiovascular Angiography and Interventions (SCAI) conference suggests that short-term outcomes are equalizing.

Lead author Dr. Anita Asgar from the Montreal Heart Institute presented results of the BRAVO 3 trial at SCAI 2016 in Orlando. The trial randomized 802 high-risk, transfemoral access TAVR patients across 31 centers in North America and Europe to one of two anticoagulation strategies: bivalirudin or unfractioned heparin. 391 women and 411 men were randomized, with a primary endpoint of major bleeding within 24 hours post-procedure. The goal was to assess whether a specific anticoagulation strategy could decrease bleeding risk in women. The results showed similar 30-day outcomes for men and women:

Rates of major bleeding at 48 hours were 10.5% in men and 9.0% in women. There was also a trend towards decreased mortality in women given bivalirudin as opposed to unfractioned heparin, although not statistically significant.

Importantly, the study only looked at outcomes up to 30-days, and other findings presented at SCAI 2016 suggest that long-term TAVR outcomes continue to differ substantially between men and women. Dr. Asgar highlights the need for longer-term research, hoping that her study will serve as a catalyst for more in-depth, longitudinal analyses of sex-based outcome improvement for TAVR patients.

Next, visit our Valve and TAVR Resource Center

Check out our Valve Resource Center to stay abreast of the latest developments in the world of TAVR and access all of our latest TAVR research, including benchmarks, best-practice studies, and unique insights.